Latisse Low Birth Weights Miscarriage

March 21, 2012 by staff 

Latisse Low Birth Weights Miscarriage, In studies on the active ingredient in Latisse and pregnancy, serious problems occurred when the drug was given to pregnant animals, such as miscarriages, fetal death, and low birth weights. However, it is unclear whether these problems would occur in humans. If you become pregnant while using it, your healthcare provider will weigh the benefits and potential risks before making a recommendation.

Can Pregnant Women Use Latisse?
LatisseĀ® (bimatoprost ophthalmic solution) is a prescription medication approved to enhance eyelashes. It is part of a group of drugs known as prostaglandins. It is not clear if Latisse is safe for use during pregnancy, as the full risks are not currently known. However, this medication has been shown to cause serious problems when given to pregnant animals.
What Is Pregnancy Category C?
The U. S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is used during pregnancy. Pregnancy Category C is given to medicines that have not been studied in pregnant humans, but do appear to cause harm to the fetus in animal studies.

In addition, medicines that have not been studied in any pregnant women or animals are automatically given a pregnancy Category C rating.

Latisse was given a pregnancy Category C rating because of problems seen in animal studies. When given to pregnant mice and rats, extremely high doses of bimatoprost (the active ingredient in Latisse) caused miscarriages. Other problems seen in these animal studies included:

Decreased gestation length (shorter pregnancies)
Increased late miscarriages
Increased fetal death
Low birth weights
Decreased survival of the newborn pups.

Latisse has not been studied in pregnant women, and it is not known if similar problems would occur in humans.

Report to Team

Please feel free to send if you have any questions regarding this post , you can contact on

Disclaimer: The views expressed on this site are that of the authors and not necessarily that of U.S.S.POST.


Comments are closed.